Jane Street Group, LLC Bei Gene, Ltd. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Jane Street Group, LLC holds 27,949 shares of BGNE stock, worth $5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,949

Previous 16,033 74.32%

Holding current value

$5 Million

Previous $2.29 Million 174.33%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $1.72 Million - $2.68 Million	11,916 Added 74.32%	27,949 $6.27 Million
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $2.08 Million - $2.79 Million	16,033 New	16,033 $2.29 Million
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $4.07 Million - $5.17 Million	-25,632 Reduced 65.37%	13,580 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $6.14 Million - $7.69 Million	34,143 Added 673.56%	39,212 $7.05 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $5,170 - $7,736	29 Added 0.58%	5,069 $903,000
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $11 Million - $14.1 Million	-51,201 Reduced 91.04%	5,040 $1.09 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $7.06 Million - $12.9 Million	56,241 New	56,241 $12.4 Million
Q2 2022 Aug 16, 2022	SELL	$121.11 - $216.05 $5.36 Million - $9.56 Million	-44,238 Reduced 76.22%	13,802 $2.23 Million
Q1 2022 May 17, 2022	BUY	$146.52 - $269.56 $4.75 Million - $8.74 Million	32,425 Added 126.59%	58,040 $10.9 Million
Q4 2021 Feb 15, 2022	BUY	$248.56 - $389.34 $5.9 Million - $9.25 Million	23,746 Added 1270.52%	25,615 $6.94 Million
Q3 2021 Nov 16, 2021	SELL	$249.6 - $403.14 $2.35 Million - $3.8 Million	-9,421 Reduced 83.45%	1,869 $678,000
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $5.03 Million - $6.31 Million	-17,186 Reduced 60.35%	11,290 $3.88 Million
Q1 2021 May 18, 2021	BUY	$260.64 - $382.12 $2.63 Million - $3.86 Million	10,104 Added 55.0%	28,476 $9.91 Million
Q4 2020 Feb 17, 2021	SELL	$221.31 - $316.61 $590,676 - $845,032	-2,669 Reduced 12.68%	18,372 $4.75 Million
Q3 2020 Nov 17, 2020	BUY	$189.18 - $286.44 $3.98 Million - $6.03 Million	21,041 New	21,041 $6.03 Million
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $824,731 - $1.01 Million	-6,838 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$113.99 - $146.86 $779,463 - $1 Million	6,838 New	6,838 $847,000
Q1 2019 May 16, 2019	SELL	$122.82 - $151.83 $337,386 - $417,077	-2,747 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$107.01 - $175.15 $665,174 - $1.09 Million	-6,216 Reduced 69.35%	2,747 $385,000
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $254,264 - $315,973	1,666 Added 22.83%	8,963 $1.54 Million
Q2 2018 Aug 15, 2018	BUY	$152.5 - $216.77 $1.11 Million - $1.58 Million	7,297 New	7,297 $1.12 Million
Q4 2017 Feb 15, 2018	SELL	$79.6 - $114.73 $260,769 - $375,855	-3,276 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $216,838 - $338,934	3,276	3,276 $339,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Bei Gene, Ltd. Transaction History